Group 1 - The core point of the news is that Changfeng Pharmaceutical has been included in the Hang Seng Composite Index, reflecting the market's recognition of the company's sustainable innovation potential and investment value in the inhalation formulation sector [1] - The inclusion in the index will take effect after the market closes on March 6, 2026, and officially on March 9, 2026 [1] - The company meets various criteria such as market capitalization, liquidity, and listing duration, which contributed to its inclusion in the index [1] Group 2 - Changfeng Pharmaceutical is an innovator in global inhalation drug delivery technology, focusing on bridging complex formulations with unmet clinical needs [2] - The company has developed a comprehensive global supply chain capability, including technologies for breath-driven nasal delivery systems and liposome inhalation [2] - The therapeutic focus includes respiratory diseases (asthma, chronic obstructive pulmonary disease, and bronchiectasis) and nasal diseases (allergic rhinitis and chronic sinusitis), with strategic expansion into pulmonary fibrosis, pulmonary hypertension, rare lung infections, and central nervous system diseases [2]
长风药业(02652)获纳入恒生综合指数 有望于3月9日进入港股通